Jan. 7 at 5:00 AM
$ARWR Some context regarding Arrowhead's
$200M stock offering and
$500M debt offering:
In the February 2025 earning conference call, there was discussion of Arrowhead's (expected by year end)
$1B cash and their aspirations to start a Cardiovascular Outcome Trial (CVOT) to expand the cardio reach of plozasiran and/or zodasiran.
President and CEO Chris Anzalone: "We'd like to do that. What we're waiting on is additional capital. ... We do have a lot of capital now, that's good, but we're going to need an influx of additional capital -- substantial additional capital before we would consider starting that... there are a ton of new targets there. We will absolutely go after some of those ourselves, and we will keep them wholly owned to expand our cardiometabolic franchise..."
Chief Medial Scientist Bruce Given: "... yes, we do like the idea of continuing to expand the reach of plozasiran."
President and CEO Chris Anzalone: "... remember that we've got other stuff going on that we think are going to drive value as well in obesity and in the CNS and the existing SATG studies alone. So yes, ... those will absorb capital as well. That's why we would need additional capital to come in, in order to start a CVOT."
Soooo, reading between the lines it looks like pedal-to-the-metal cardio expansion trials are imminent!
